DGX insider ownership: who sold, why, and what they still hold

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Davis J. E. CEO and President, Director	10,000	$242.72	7.6%	122K	Sep 1, 2026	Sep 3, 2026

What stands out

Three officers sold more than 25% of vested holdings: Davis J. E. (67% of holdings, $17.1M, all under a disclosed plan), Catherine Doherty (47% of holdings, $7.0M, all under a disclosed plan) and Patrick Plewman (65% of holdings, $2.0M, all under a disclosed plan).Davis J. E.: largest sale, Nov 25, 2025 · Catherine Doherty: largest sale, Feb 13, 2026 · Patrick Plewman: largest sale, Feb 10, 2026

Two directors sold shares but ended with larger stakes, because more shares came in than were sold: Gary Pfeiffer (sold 1.5K, 4.8% of starting holdings; 1.8K added) and Vicky Gregg (sold 1.2K, 6.9% of starting holdings; 1.4K added).Gary Pfeiffer: largest sale, Oct 22, 2025 · Vicky Gregg: largest sale, Nov 25, 2025

Percentages cover 14 of 18 officers and directors. 4 are left out

Left out: Michael Prevoznik and Mark Delaney (most of their shares vested during the period, so a percentage would mislead); Karthik Kuppusamy (holdings couldn't be fully reconciled); Timothy Wentworth (held no vested shares at the start).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is 100% of that person's own stake; not comparable between people. The stake is the vested shares held at the start of the period (Oct 9, 2025); the gold part is what they sold.

SoldRest of starting stakeAdded during the period

Davis J. E.

CEO and President, Director

67% · $17.1MDisclosed plan

Catherine Doherty

EVP, Regional Businesses

47% · $7.0MDisclosed plan

Michael Prevoznik

SVP & General Counsel

Sold $6.6M (plan status beside the amount). That is 39% of the shares held or received (after tax withholding) during the period†. A share of the starting stake is not shown: most of these shares arrived during the period. Why

$6.6MDisclosed plan

Karthik Kuppusamy

SVP, Clinical Solutions

Sold $2.2M (plan status beside the amount). Share of stake not shown: holdings couldn't be fully reconciled. Why

$2.2M75% planned, 25% to cover taxes

Patrick Plewman

SVP for Diagnostic Services

Sold 65%, but 5.7K shares were added (mostly vesting), so the stake grew

65% · $2.0MDisclosed plan

All 8 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Common questions

Is the Quest Diagnostics CEO selling stock?

Yes. Davis J. E. sold 85K shares ($17.1M, 67% of starting holdings) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Quest Diagnostics insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 97% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 1% were to cover taxes and 1% had no disclosed plan. A trading plan schedules sales in advance.

Are any Quest Diagnostics insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

How much of their stake did Quest Diagnostics insiders sell?

About 32% overall. As a group they ended with more shares than they started with. The biggest individual seller, Davis J. E., gave up 67% of starting holdings. That covers the 12 months to Oct 9, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold8 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Davis J. E. CEO and President, Director	$17.1M 85K shares	67%	Disclosed plan
Catherine Doherty EVP, Regional Businesses	$7.0M 34K shares	47%	Disclosed plan
Michael Prevoznik SVP & General Counsel	$6.6M 28K shares	39%† i † Most of the shares Michael Prevoznik sold arrived during the period, so this is shares sold as a share of the 44K held at the start plus the 32K received, less 4.3K withheld by the company for taxes.	Disclosed plan
Karthik Kuppusamy SVP, Clinical Solutions	$2.2M 11K shares	i No percentage: holdings couldn't be fully reconciled.	75% under a disclosed plan, 25% to cover taxes
Patrick Plewman SVP for Diagnostic Services	$2.0M 9.9K shares	65%	Disclosed plan
Mark Delaney SVP & Chief Commercial Officer	$1.9M 9.5K shares	48%† i † Most of the shares Mark Delaney sold arrived during the period, so this is shares sold as a share of the 7.5K held at the start plus the 15K received, less 2.9K withheld by the company for taxes.	Disclosed plan
Gary Pfeiffer Director	$270K 1.5K shares	4.8%	No plan disclosed
Vicky Gregg Director	$240K 1.3K shares	6.9%	No plan disclosed

The full ownership picture17 of 18 insiders fully reconciled · 18 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 9, 2025

Sold

Held Oct 9, 2026

Still held

Davis J. E.

Includes unvested RSUs, amount not disclosed.

CEO and President, Director

128K

−85K

122K

96%

Vesting, gifts, unvested awards and holding lines for Davis J. E.

+55Kshares vested or exercised

0gifted (net of own trusts)

−43Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	127,623	122,423

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
92,779	$127.81	Feb 14, 2034	$10.7M
69,633	$165.30	Feb 12, 2035	$5.4M
73,225	$204.96	Feb 18, 2036	$2.8M

Estimate: options held × ($242.72 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Catherine Doherty

Minor difference of 75 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed. Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

EVP, Regional Businesses

72K

−34K

72K

99%

Vesting, gifts, unvested awards and holding lines for Catherine Doherty

+26Kshares vested or exercised

0gifted (net of own trusts)

−7.6Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	68,068	67,122
401(k)/SDCP	Common Stock	4,427	4,502

Additional holdings last reported Jan 30, 2017, not confirmed since: 294 shares. Not included in any total or percentage on this page.

SDCP, Common Stock: 294 shares, last reported Jan 30, 2017

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
17,939	$127.81	Feb 14, 2034	$2.1M
13,344	$165.30	Feb 12, 2035	$1.0M
13,514	$204.96	Feb 18, 2036	$510K

Estimate: options held × ($242.72 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Reconciliation: minor difference of 75 shares. Difference is under 0.5% of holdings.

Michael Prevoznik

Minor difference of 88 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed. Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

SVP & General Counsel

44K

−28K

42K

not meaningful

Vesting, gifts, unvested awards and holding lines for Michael Prevoznik

+23Kshares vested or exercised

−1Kgifted (net of own trusts)

−4.3Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	38,117	36,557
401(k)/SDCP	Common Stock	5,692	5,780

Additional holdings last reported Oct 14, 2020, not confirmed since: 9,744 shares. Not included in any total or percentage on this page.

401K, Common Stock: 5,174 shares, last reported Oct 14, 2020
401k/SDCP, Common Stock: 4,570 shares, last reported Aug 4, 2014

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
12,231	$127.81	Feb 14, 2034	$1.4M
8,991	$165.30	Feb 12, 2035	$696K
9,289	$204.96	Feb 18, 2036	$351K

Estimate: options held × ($242.72 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Reconciliation: minor difference of 88 shares. Difference is under 0.5% of holdings.

Michael Deppe

Minor difference of 24 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed. Class as filed looks like a typo ("401(k)"); treated as Common Stock.

SVP, Corp. Controller & CAO

35K

36K

no sales

Vesting, gifts, unvested awards and holding lines for Michael Deppe

0shares vested or exercised

0gifted (net of own trusts)

−1Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Class as filed looks like a typo ("401(k)"); treated as Common Stock. Filing 1 Filing 2 Filing 3 Filing 4 Filing 5 Filing 6 Filing 7 Filing 8 Filing 9 Filing 10 Filing 11 Filing 12 Filing 13 Filing 14 Filing 15 Filing 16 Filing 17 Filing 18

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	34,365	35,196
401(k)	Common Stock	694	706

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
2,322	$127.81	Feb 14, 2034	$267K
1,738	$165.30	Feb 12, 2035	$135K
1,688	$204.96	Feb 18, 2036	$64K

Estimate: options held × ($242.72 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Reconciliation: minor difference of 24 shares. Difference is under 0.5% of holdings.

Gary Pfeiffer

Minor difference of 676 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends. Includes unvested RSUs, amount not disclosed. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Director

31K

−1.5K

31K

+1.1%

Vesting, gifts, unvested awards and holding lines for Gary Pfeiffer

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	30,669	31,005

Reconciliation: minor difference of 676 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Timothy Ring

Minor difference of 491 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends. Includes unvested RSUs, amount not disclosed. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Director

30K

31K

no sales

Vesting, gifts, unvested awards and holding lines for Timothy Ring

0shares vested or exercised

0gifted (net of own trusts)

127K → 127Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	29,507	31,140

Reconciliation: minor difference of 491 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Timothy Main

Includes unvested RSUs, amount not disclosed.

Director

26K

27K

no sales

Vesting, gifts, unvested awards and holding lines for Timothy Main

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	26,297	22,460
Trust	Common Stock	0	5,000

Sam Samad

Includes unvested RSUs, amount not disclosed.

Executive Vice President & CFO

26K

33K

no sales

Vesting, gifts, unvested awards and holding lines for Sam Samad

0shares vested or exercised

0gifted (net of own trusts)

−10Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	25,673	33,478

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
22,835	$127.81	Feb 14, 2034	$2.6M
17,403	$165.30	Feb 12, 2035	$1.3M
18,303	$204.96	Feb 18, 2036	$691K

Estimate: options held × ($242.72 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Vicky Gregg

Includes unvested RSUs, amount not disclosed.

Director

18K

−1.3K

18K

+0.9%

Vesting, gifts, unvested awards and holding lines for Vicky Gregg

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	18,217	18,386

Patrick Plewman

Minor difference of 18 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed.

SVP for Diagnostic Services

15K

−9.9K

15K

+0.2%

Vesting, gifts, unvested awards and holding lines for Patrick Plewman

+5.7Kshares vested or exercised

0gifted (net of own trusts)

−3.6Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	15,269	15,293

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
10,190	$127.81	Feb 14, 2034	$1.2M
7,833	$165.30	Feb 12, 2035	$606K
9,009	$204.96	Feb 18, 2036	$340K

Estimate: options held × ($242.72 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Reconciliation: minor difference of 18 shares. Difference is under 0.5% of holdings.

Denise Morrison

Minor difference of 45 shares. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed.

Director

11K

12K

no sales

Vesting, gifts, unvested awards and holding lines for Denise Morrison

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	10,742	11,929

Reconciliation: minor difference of 45 shares. Difference is under 0.5% of holdings.

Karthik Kuppusamy

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +93 shares on Apr 20, 2026 (401(k)). See the filing Sales and other transactions for Karthik Kuppusamy are complete.

SVP, Clinical Solutions

n/a

−11K

n/a

Vesting, gifts, unvested awards and holding lines for Karthik Kuppusamy

+8.1Kshares vested or exercised

0gifted (net of own trusts)

−716withheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Class as filed looks like a typo ("401(k)"); treated as Common Stock. Filing 1 Filing 2

Holdings couldn't be fully reconciled. Balance changed without a matching transaction, and the footnote does not state the amount: +93 shares on Apr 20, 2026 (401(k)). The balances below are as reported, not verified totals.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	8,338	13,557
401(k)	Common Stock	1,628	1,691
Trust	Common Stock	358	358

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
11,007	$127.81	Feb 14, 2034	$1.3M
8,702	$165.30	n/a	$674K
9,853	$204.96	Feb 18, 2036	$372K

Estimate: options held × ($242.72 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Wright Lassiter III

Minor difference of 118 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends. Includes unvested RSUs, amount not disclosed. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Director

10K

no sales

Vesting, gifts, unvested awards and holding lines for Wright Lassiter III

0shares vested or exercised

0gifted (net of own trusts)

1.7K → 1.7Kunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	9,044	10,323

Reconciliation: minor difference of 118 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Mark Delaney

Includes unvested RSUs, amount not disclosed.

SVP & Chief Commercial Officer

7.5K

−9.5K

10K

not meaningful

Vesting, gifts, unvested awards and holding lines for Mark Delaney

+7.9Kshares vested or exercised

0gifted (net of own trusts)

−2.9Kwithheld by the company for taxes

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	7,515	10,335

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
7,484	$143.33	Feb 23, 2033	$744K
9,783	$127.81	Feb 14, 2034	$1.1M
6,960	$165.30	Feb 12, 2035	$539K
7,332	$204.96	Feb 18, 2036	$277K

Estimate: options held × ($242.72 − strike price), using the most recent insider trade price on Form 4 (Sep 1, 2026), not a market close.

Tracey Doi

Minor difference of 116 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends. Includes unvested RSUs, amount not disclosed. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Director

6.5K

7.7K

no sales

Vesting, gifts, unvested awards and holding lines for Tracey Doi

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.
Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	6,490	7,748

Reconciliation: minor difference of 116 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Luis Diaz

Includes unvested RSUs, amount not disclosed.

Director

4.1K

5.2K

no sales

Vesting, gifts, unvested awards and holding lines for Luis Diaz

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	4,054	5,196

Robert Carter

Includes unvested RSUs, amount not disclosed.

Director

2.7K

3.9K

no sales

Vesting, gifts, unvested awards and holding lines for Robert Carter

0shares vested or exercised

0gifted (net of own trusts)

none reportedunvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	2,692	3,864

Timothy Wentworth

Minor difference of 1 share. Difference is under 0.5% of holdings. Includes unvested RSUs, amount not disclosed.

Director

1.4K

no sales

Vesting, gifts, unvested awards and holding lines for Timothy Wentworth

0shares vested or exercised

0gifted (net of own trusts)

0 → 477unvested awards, start → end

Includes unvested RSUs, amount not disclosed.

Held through	Share class	Oct 9, 2025	Oct 9, 2026
Direct includes unvested RSUs, amount not disclosed	Common Stock	0	1,358

Reconciliation: minor difference of 1 share. Difference is under 0.5% of holdings.

17 of 18 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (7 exactly, 10 with a minor or footnoted difference). For 1 we show sales but not holdings; the ! icon on that row explains why. Percentages cover 14 of 18 officers and directors. Left out: Michael Prevoznik and Mark Delaney (most of their shares vested during the period, so a percentage would mislead); Karthik Kuppusamy (holdings couldn't be fully reconciled); Timothy Wentworth (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$37.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $37.3M across 180,011 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $36.2M · 97%

The lighter segment is sales with no plan disclosed in the filing ($1.0M), including tax-related sales outside a plan.

No plan disclosed · $510K

Sales with no 10b5-1 plan and no tax reference in the filing. $270K of it is Gary Pfeiffer. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Gary Pfeiffer, Oct 22, 2025

Taxes

$538K of sales (1.4%) cite tax obligations in their footnotes. Separately, 73,347 shares ($14.9M) were withheld by the company for taxes, which isn't a market sale. Example: Karthik Kuppusamy, Mar 4, 2026

Charitable gifts · 1K shares

Gifts the filings describe as charitable. Gifts are not sales and are not included in the sale totals.

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Davis J. E. CEO and President, Director	85K	$17.1M	100%	46%	Nov 25, 2025 to Sep 1, 2026
Catherine Doherty EVP, Regional Businesses	34K	$7.0M	100%	19%	Feb 13, 2026 to Mar 5, 2026
Michael Prevoznik SVP & General Counsel	28K	$6.6M	100%	18%	Feb 19, 2026 to Aug 28, 2026
Karthik Kuppusamy SVP, Clinical Solutions	11K	$2.2M	75%	6%	Mar 4, 2026 to Jun 4, 2026
Patrick Plewman SVP for Diagnostic Services	9.9K	$2.0M	100%	5%	Feb 10, 2026 to Mar 5, 2026
Mark Delaney SVP & Chief Commercial Officer	9.5K	$1.9M	100%	5%	Nov 18, 2025 to Jul 28, 2026
Gary Pfeiffer Director	1.5K	$270K	0%	0.7%	Oct 22, 2025 to Oct 22, 2025
Vicky Gregg Director	1.3K	$240K	0%	0.6%	Nov 25, 2025 to Nov 25, 2025

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$270K	$0	$0	$270K
Nov 2025	$12.3M	$12.1M	$0	$240K
Dec 2025	$0	$0	$0	$0
Jan 2026	$0	$0	$0	$0
Feb 2026	$7.3M	$7.3M	$0	$0
Mar 2026	$5.5M	$5.0M	$538K	$0
Apr 2026	$0	$0	$0	$0
May 2026	$0	$0	$0	$0
Jun 2026	$3.6M	$3.6M	$0	$0
Jul 2026	$376K	$376K	$0	$0
Aug 2026	$5.5M	$5.5M	$0	$0
Sep 2026	$2.4M	$2.4M	$0	$0
Oct 2026	$0	$0	$0	$0

Is this normal? Selling year by year5 earlier years to compare with

Less than usual: about two-thirds of the 5-year average. 8 insiders sold; the average is 6 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 9, 2026 Latest 12 months	180K	8	$37.3M
Oct 9, 2025 1 year earlier	202K	8	$34.1M
Oct 9, 2024 2 years earlier	53K	5	$7.7M
Oct 10, 2023 3 years earlier	75K	4	$11.0M
Oct 10, 2022 4 years earlier	499K	4	$70.4M
Oct 10, 2021 5 years earlier	698K	7	$88.9M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty1 insider whose holdings couldn't be fully reconciled

Karthik Kuppusamy: holdings couldn't be fully reconciled (difference of 184 shares). Balance changed without a matching transaction, and the footnote does not state the amount: +93 shares on Apr 20, 2026 (401(k)). Filing, Apr 20, 2026

Footnote: "These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under the Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date."

Catherine Doherty: minor difference of 75 shares. Difference is under 0.5% of holdings.

Michael Prevoznik: minor difference of 88 shares. Difference is under 0.5% of holdings.

Michael Deppe: minor difference of 24 shares. Difference is under 0.5% of holdings.

Gary Pfeiffer: minor difference of 676 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Timothy Ring: minor difference of 491 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Patrick Plewman: minor difference of 18 shares. Difference is under 0.5% of holdings.

Denise Morrison: minor difference of 45 shares. Difference is under 0.5% of holdings.

Wright Lassiter III: minor difference of 118 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Tracey Doi: minor difference of 116 shares. Unexplained small increases, consistent with stock unit vesting or reinvested dividends.

Timothy Wentworth: minor difference of 1 share. Difference is under 0.5% of holdings.

Inferred rename: "Spouse" is treated as the same holder as "UGMA", because the old name was never reported again and the new one opened with the same balance (864 shares). Old name, new name

Inferred typo: the share class "Common stock par value $0.01 per share" is treated as the same class as "Common Stock par value, $0.01 per share" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (GLAXOSMITHKLINE PLC, 30,755,151 shares): old title, new title

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology1,444 filings from SEC EDGAR, and how we read them

All 1,444 Forms 3, 4 and 5 filed for Quest Diagnostics (SEC CIK 1022079) from Jun 30, 2003 to Oct 2, 2026, retrieved from SEC EDGAR on Oct 9, 2026. Prices are the ones reported in each filing, often weighted averages. 7 filings were left out because Quest Diagnostics filed them as an owner of another company's stock.

Probable 2-for-1 stock split on or before Oct 1, 2005 (first filing that shows post-split balances). Splits aren't reported as transactions; 6 holding lines changed by exactly this ratio, so earlier share counts are restated.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (34)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Mark Gardner	Sep 26, 2024	4,673 shares, last reported balance as of Sep 24, 2024
Gail Wilensky	May 19, 2023	33,881 shares, last reported balance as of May 17, 2023
Stephen Rusckowski	Mar 8, 2023	389,597 shares, last reported balance as of Mar 6, 2023
Mark Guinan	Mar 9, 2022	98,981 shares, last reported balance as of Mar 7, 2022
Manner Eglinton	Mar 9, 2022	48,391 shares, last reported balance as of Mar 7, 2022
Helen Torley	May 25, 2021	6,260 shares, last reported balance as of May 25, 2021
Manuel Mendez	Feb 22, 2021	29,045 shares, last reported balance as of Feb 17, 2021
Daniel Stanzione	Nov 24, 2020	28,349 shares, last reported balance as of Nov 23, 2020
Everett Cunningham	Mar 25, 2019	39,032 shares, last reported balance as of Mar 4, 2019
Robert Klug	Mar 5, 2019	6,261 shares, last reported balance as of Mar 1, 2019
Jenne Britell	Jun 6, 2018	20,504 shares, last reported balance as of Jun 4, 2018
Jeffrey Leiden	May 30, 2018	6,000 shares, last reported balance as of May 29, 2018
Jon Cohen	Mar 12, 2018	31,757 shares, last reported balance as of Mar 8, 2018
John Ziegler	Feb 24, 2017	16,557 shares, last reported balance as of Feb 22, 2017
John Baldwin	Aug 13, 2015	12,949 shares, last reported balance as of Aug 12, 2015
Thomas Bongiorno	Mar 3, 2015	23,816 shares, last reported balance as of Mar 2, 2015
John Haydon	Feb 18, 2014	19,890 shares, last reported balance as of Feb 13, 2014
William Buehler	Feb 14, 2014	26,225 shares, last reported balance as of Feb 12, 2014
Kathy Ordonez	Apr 2, 2013	9,569 shares, last reported balance as of Mar 31, 2013
Robert Hagemann	Mar 7, 2013	168,990 shares, last reported balance as of Mar 5, 2013
Surya Mohapatra	May 2, 2012	259,530 shares, last reported balance as of Apr 30, 2012
Joan Miller	Mar 2, 2012	94,758 shares, last reported balance as of Feb 29, 2012
Wayne Simmons	Jun 20, 2011	48,335 shares, last reported balance as of Jun 16, 2011
GLAXOSMITHKLINE PLC	Feb 2, 2011	36,504,308 shares, last reported balance as of Sep 15, 2008
Rosanne Haggerty	May 10, 2010	9,334 shares, last reported balance as of May 6, 2010
William Grant	Apr 3, 2007	3,334 shares, last reported balance as of Apr 1, 2007
David Zewe	Feb 13, 2007	40,970 shares, last reported balance as of Feb 12, 2007
Robert Peters	Feb 13, 2007	16,854 shares, last reported balance as of Feb 12, 2007
Thomas Grant II	Feb 13, 2007	4,793 shares, last reported balance as of Feb 12, 2007
James Flaherty III	May 8, 2006	3,667 shares, last reported balance as of May 4, 2006
Kenneth Freeman	Dec 14, 2004	443,302 shares, last reported balance as of Dec 14, 2004
Kenneth Brody	Apr 28, 2004	No balance on record
Mary Cirillo	Apr 5, 2004	5,254 shares, last reported balance as of Apr 1, 2004
Gerald Marrone	Mar 2, 2004	108,988 shares, last reported balance as of Feb 28, 2004

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Quest Diagnostics insiders sold $37.3M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Common questions

Is the Quest Diagnostics CEO selling stock?

Why are Quest Diagnostics insiders selling?

Are any Quest Diagnostics insiders buying?

How much of their stake did Quest Diagnostics insiders sell?

The evidence

No plan disclosed · $510K

Taxes

Charitable gifts · 1K shares

Sales by month